FDA Suspends License of Gayatri Mewad in Chhatrapati Sambhajinagar Over Safety Lapses - LatestLY
FDA has suspended the license of Gayatri Mewad due to safety lapses, impacting their ability to operate legally.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 22, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Gayatri Mewad and potentially other manufacturers in the region. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed. Regulated niches like Pharmaceutical Manufacturing (FDA/DEA) move faster than most operators can track by hand, which is why Aforeworn watches the official sources for you and flags every material change the moment it appears.
What changed
Suspension of operating license due to safety compliance failures.
Who it affects
Gayatri Mewad and potentially other manufacturers in the region.
What you must do
Address safety compliance issues to seek reinstatement of the license.
Deadline
Not specified.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Commissioner's National Priority Voucher (CNPV) Pilot Program - fda.gov
- FDA warns firm for inappropriate use of AI in drug manufacturing - RAPS
- DEA Urges Judge to Move Marijuana to Schedule III as Final Rescheduling Briefs Set Stage for Decision - The Marijuana Herald
- 5,000 ppm fluoride toothpaste needs expert guidance, FDA says - Nation Thailand
- FDA issues draft guidance on assessing container and closure systems for drugs and biologics - RAPS